Global study targets dengue as disease threatens nearly half the world’s population
LISMORE, Australia, Dec. 18, 2025 /PRNewswire/ -- Thousands of dengue forecasting models…
NEXTCHEM (MAIRE) AWARDED A FEASIBILITY STUDY BY RHM FOR A PMMA-POLYMER CHEMICAL RECYCLING PLANT IN GERMANY BASED ON ITS PROPRIETARY NXRe TECHNOLOGY
NEXTCHEM will develop a site-specific feasibility study for a chemical plastic recycling…
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE:…
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
December 11, 2025 18:22 ET | Source: Mesoblast Limited NEW YORK, Dec.…
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
Medit recognized as the top brand in a global brand perception study by an external insights agency
Global sentiment analysis of 3,800 discussions from Reddit's r/Dentistry community highlights strong…
Junshi Biosciences Announces Primary Endpoints Met in JS001scs Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
IBM Study: Chief Data Officers Redefine Strategies as AI Ambitions Outpace Readiness
81% of Chief Data Officers surveyed prioritize investments that accelerate AI capabilities…
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
November 08, 2025 11:45 ET | Source: Vor Biopharma Treatment with telitacicept…
Nanoscope Therapeutics Reports Five-Year Safety Results from Phase 1/2a Follow-Up Study of MCO-010 Optogenetic Therapy in Retinitis Pigmentosa
DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive…
